Atrial natriuretic peptide and long-acting natriuretic peptide inhibit ras in human prostate cancer cells.

Autor:	Sun Y; Department of Internal Medicine, University of South Florida Cardiac Hormone Center, and James A. Haley Veterans Medical Center-151, Tampa, Florida 33612, U.S.A., Eichelbaum EJ, Lenz A, Skelton WP 4th, Wang H, Vesely DL
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2009 Jun; Vol. 29 (6), pp. 1889-93.
Abstrakt:	Background: Atrial natriuretic peptide and long-acting natriuretic peptide have anticancer effects in human prostate adenocarcinoma. Materials and Methods: The effects of atrial natriuretic peptide and long-acting natriuretic peptide and cyclic GMP on Ras were examined in human prostate adenocarcinoma cells. Results: Atrial natriuretic peptide and long-acting natriuretic peptide reduced the activation of Ras-GTP over a concentration range of 0.01 microM to 1 microM. Atrial natriuretic peptide and long-acting natriuretic peptide (each 0.1 microM) inhibited the phosphorylation of Ras 90% (p<0.0001) and 83% (p<0.0001), respectively. At 0.01 microM of long-acting natriuretic peptide, the maximal inhibition was 89%, which occurred within 5 minutes. Both peptide hormones inhibited Ras for 24 hours. Their ability to inhibit Ras was inhibited by cyclic GMP antibody and cyclic GMP itself inhibited Ras phosphorylation (72%; p=0.009). Conclusion: Atrial natriuretic peptide and long-acting natriuretic peptide both inhibit Ras partially mediated via cyclic GMP as part of their anticancer mechanism(s) of action.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu